Predicting the response of advanced cervical and ovarian tumors to therapy

Obstetrical and Gynecological Survey

Volumn 64, Issue 8, 2009, Pages 548-560

  Harry, Vanessa N ^a   Gilbert, Fiona J ^b   Parkin, David E ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADVANCED CANCER; CANCER GRADING; CANCER SIZE; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; GENE EXPRESSION PROFILING; HEALTH CARE COST; HUMAN; IN VITRO STUDY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; REVIEW; TOXICITY; TREATMENT RESPONSE; UTERINE CERVIX CANCER; FEMALE; FORECASTING; OVARY TUMOR; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

FEMALE; FORECASTING; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 70349574111     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181abc114     Document Type: Review

References (163)

1. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153. (Pubitemid 29177873)
2. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340: 1137-1143. (Pubitemid 29177872)
3. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
4. Souhami L, Seymour R, Roman TN, et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1993;27:871-878. (Pubitemid 23340299)
5. Souhami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 1991;9:970-977.
6. National Institute for Clinical Excellence (NICE). Guidance on the Use of Taxanes for Ovarian Cancer. London: NICE guidelines, 2000.
7. McNally OM, Delaney E, Petty RD, et al. Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study. Br J Cancer 2003;89: 966-967. (Pubitemid 37239195)
8. Dent TH, Sadler M. From guidance to practice: why NICE is not enough. BMJ 2002;324:842-845. (Pubitemid 34280740)
9. Hensel M, Schneeweiss A, Sinn HP, et al. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 2002;100:290296. (Pubitemid 34728986)
10. Dose Schwarz J, Bader M, Jenicke L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:11441150. (Pubitemid 43741076)
11. Van de Vijver MJ, He YD, Van't Veer, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
12. Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006;94:427-435. (Pubitemid 43237566)
13. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360:307-308. (Pubitemid 34874724)
14. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91: 475-481.
15. Ozsarlak O, Tjalma W, Schepens E, et al. The correlation of preoperative CT, MR imaging, and clinical staging (FIGO) with histopathology findings in primary cervical carcinoma. Eur Radiol 2003;13:2338-2345.
16. Bipat S, Glas AS, van der Velden J, et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol 2003;91:59-66. (Pubitemid 37188594)
17. Hawnaur JM, Johnson RJ, Carrington BM, et al. Predictive value of clinical examination, transrectal ultrasound, and magnetic resonance imaging prior to radiotherapy in carcinoma of the cervix. Br J Radiol 1998;71:819-827.
18. Ozsaran Z, Kamer S, Yalman D, et al. Treatment results and prognostic factors for cervical cancer patients treated by radiochemotherapy with weekly cisplatin. Eur J Gynaecol Oncol 2007;28:196-200. (Pubitemid 46985641)
19. Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007;109:1342-1350. (Pubitemid 46869873)
20. Skirnisdottir I, Sorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int J Oncol 2007;30:727-734.
21. Bishara S, Griffin M, Cargill A, et al. Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2008;138:71-75. (Pubitemid 351608106)
22. Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopybased score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13:1156-1161. (Pubitemid 44337976)
23. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001;38:225-262. (Pubitemid 32614076)
24. Schrag D, Garewal HS, Burstein HJ, et al. American society of clinical oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22: 3631-3638. (Pubitemid 41103670)
25. Fruehauf JP. In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 2002;9:171-182.
26. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461-463.
27. Fruehauf JP, Bosanquet AG. In vitro determinations of drug response: a discussion of clinical applications. PPO Updates 1993;7:1-16.
28. Taylor CG, Sargent JM, Elgie AW, et al. The clinical relevance of chemosensitivity testing in ovarian cancer. Cancer Detect Prev 1998;22:305-312. (Pubitemid 28310123)
29. Agiostratidou G, Sgouros I, Galani E, et al. Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients. Anticancer Res 2001 ;21 : 455-459. (Pubitemid 32267682)
30. Ferrandina G, Scambia G, Damia G, et al. Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol 1997;8:343-350. (Pubitemid 27230974)
31. Ng TY, Ngan HY, Cheng DK, et al. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynecol Oncol 2000;76:405-408.
32. Maenpaa JU, Heinonen E, Hinkka SM, et al. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol 1995;57:294298.
33. O'Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001;83:334-342.
34. Von Hoff DD, Kronmal R, Salmon SE, et al. A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991;67:20-27.
35. Taylor CG, Sargent JM, Elgie AW, et al. Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol 2001;22:278-282. (Pubitemid 32976904)
36. Holloway RW, Mehta RS, Finkler NJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 2002;87:8-16.
37. Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000;77: 258-263. (Pubitemid 30317146)
38. Monk BJ, Burger RA, Parker R, et al. Development of an in vitro chemo-radiation response assay for cervical carcinoma. Gynecol Oncol 2002;87:193-199. (Pubitemid 36044086)
39. Xiao Y, Li JD, Shi HL, et al. Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer [in Chinese]. Ai Zheng 2007;26:386-389.
40. West CM, Davidson SE, Roberts SA, et al. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 1993;68:819-823. (Pubitemid 23301293)
41. Mehta RS, Bornstein R, Yu IR, et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 2001 ;66:225-237. (Pubitemid 32675025)
42. Orr JW Jr, Orr P, Kern DH. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sei Am 1999;5:174-178. (Pubitemid 29252433)
43. Loizzi V, Chan JK, Osann K, et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 2003;189:1301-1307. (Pubitemid 37542162)
44. van der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70-78.
45. Hamada S, Kamada M, Furumoto H, et al. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994;52:313-319. (Pubitemid 24125546)
46. Verma M, Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 2003;163:72-84; discussion 264-266.
47. Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 2005;25:107-125.
48. Marjoniemi VM. Immunohistochemistry in gynaecological pathology: a review. Pathology 2004;36:109-119.
49. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 2002;40: 309-326. (Pubitemid 34595581)
50. Loncaster JA, Cooper RA, Logue JP, et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000;83:620-625. (Pubitemid 30636303)
51. Hazelbag S, Kenter GG, Gorter A, et al. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 2004;112:1020-1028. (Pubitemid 39507009)
52. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor-1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-4696. (Pubitemid 30701471)
53. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor-1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234-2240. (Pubitemid 36687648)
54. Distefano M, Ferrandina G, Smaniotto D, et al. Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology 2004;67:103111. (Pubitemid 39482677)
55. Ferrandina G, Ranelletti FO, Legge F, et al. Cyclooxygenase2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery. Int J Radiat Oncol Biol Phys 2003;55:21-27. (Pubitemid 36020340)
56. Ferrandina G, Lauriola L, Zannoni GF, et al. Expression of cyclooxygenase-2 (COX-2) in tumor and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002;87:1145-1152. (Pubitemid 35418111)
57. Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973-981. (Pubitemid 34141840)
58. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13:1205-1211. (Pubitemid 34960128)
59. Raspollini MR, Amunni G, Villanucci A, et al. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 2005;15:255260. (Pubitemid 40396961)
60. Ferrandina G, Ranelletti FO, Martinelli E, et al. Cyclooxygenase-2 (cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer 2006;6:182. (Pubitemid 44203872)
61. Kigawa J, Minagawa Y, Kanamori Y, et al. Glutathione concentration may be a useful predictor of response to secondline chemotherapy in patients with ovarian cancer. Cancer 1998;82:697-702. (Pubitemid 28090281)
62. Walker G, MacLeod K, Williams AR, et al. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 2007;13:1438-1444.
63. Lavarino C, Pilotti S, Oggionni M, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000;18:3936-3945.
64. Ferrandina G, Fagotti A, Salerno MG, et al. P53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999;81:733-740. (Pubitemid 29458874)
65. Marx D, Meden H, Ziemek T, et al. Expression of the p53 tumor suppressor gene as a prognostic marker in platinumtreated patients with ovarian cancer. Eur J Cancer 1998;34: 845-850. (Pubitemid 28248495)
66. West CM, McKay MJ, Holscher T, et al. Molecular markers predicting radiotherapy response: report and recommendations from an international atomic energy agency technical meeting. Int J Radiat Oncol Biol Phys 2005;62:1264-1273. (Pubitemid 40982043)
67. Habeck M. DNA microarray technology to revolutionize cancer treatment. Lancet Oncol 2001 ;2:5.
68. Bertucci F, Houlgatte R, Nguyen C, et al. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? Lancet Oncol 2001;2:674-682.
69. Bryant-Greenwood P. Molecular diagnostics in obstetrics and gynecology. Clin Obstet Gynecol 2002;45:605-621.
70. Wong YF, Selvanayagam ZE, Wei N, et al. Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res 2003;9:5486-5492. (Pubitemid 37499466)
71. Kitahara O, Katagiri T, Tsunoda T, et al. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 2002;4:295-303. (Pubitemid 34755839)
72. Achary MP, Jaggernauth W, Gross E, et al. Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression. Cytogenet Cell Genet 2000;91:39-43. (Pubitemid 32110337)
73. Lyng H, Brovig RS, Svendsrud DH, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 2006;7:268. (Pubitemid 44650240)
74. Kudoh K, Ramanna M, Ravatn R, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicinresistant cancer cells by cDNA microarray. Cancer Res 2000; 60:4161-4166. (Pubitemid 30636599)
75. Chung YM, Kim BG, Park CS, et al. Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer 2005;117:194-201. (Pubitemid 41377438)
76. De Smet F, Pochet NL, Engelen K, et al. Predicting the clinical behavior of ovarian cancer from gene expression profiles. Int J Gynecol Cancer 2006;16:147-151.
77. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-525. (Pubitemid 350002958)
78. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-4710.
79. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005; 11:3686-3696. (Pubitemid 40685585)
80. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005;11: 2149-2155.
81. Lancaster JM, Dressman HK, Clarke JP, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006; 16:1733-1745.
82. Helleman J, Jansen MP, Span PN, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006; 118: 1963-1971.
83. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:63006310.
84. Sakamoto M, Kondo A, Kawasaki K, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 2001;14:305-315.
85. Selvanayagam ZE, Cheung TH, Wei N, et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 2004; 154:63-66. (Pubitemid 39286175)
86. Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337. (Pubitemid 12235035)
87. Jacobs I, Bast RC Jr. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12. (Pubitemid 19069900)
88. Redman CW, Blackledge GR, Kelly K, et al. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990;26:593-596. (Pubitemid 20259337)
89. van der Burg ME, Lammes FB, van Putten WL, et al. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988;30: 307-312.
90. Mogensen O, Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992;44:207-212.
91. Mogensen O, Mogensen B, Jakobsen A. Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol 1990;37:44-46. (Pubitemid 20147968)
92. Makar AP, Kristensen GB, Bormer OP, et al. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993;49:3-7.
93. Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006; 103: 195-198. (Pubitemid 44389869)
94. Peters-Engl C, Medl M, Ogris E, et al. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Anticancer Res 1995; 15:2727-2730. (Pubitemid 26095089)
95. Coleman RL, Gordon A, Barter J, et al. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 2007;12:72-78. (Pubitemid 46143504)
96. Scambia G, Benedetti Panici P, Foti E, et al. Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol 1994;12:2309-2316. (Pubitemid 24346700)
97. Rose PG, Baker S, Fournier L, et al. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. Am J Obstet Gynecol 1993; 168:942-946. (Pubitemid 23096025)
98. Hong JH, Tsai CS, Chang JT, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:823-830. (Pubitemid 28285960)
99. Duk JM, Groenier KH, de Bruijn HW, et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 1996;14:111-118.
100. Ohno T, Nakayama Y, Nakamoto S, et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer 2003;97:3114-3120. (Pubitemid 36676268)
101. Yoon SM, Shin KH, Kim JY, et al. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy. Int J Gynecol Cancer 2007;17:872-878. (Pubitemid 47063328)
102. Bae SN, Namkoong SE, Jung JK, et al. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1997;64:418-424. (Pubitemid 27120429)
103. Sonoda K, Nakashima M, Kaku T, et al. A novel tumorassociated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996;77:1501-1509. (Pubitemid 26105386)
104. Sonoda K, Miyamoto S, Hirakawa T, et al. Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol Oncol 2005; 97:772-779. (Pubitemid 40824645)
105. Sonoda K, Miyamoto S, Yotsumoto F, et al. Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol Rep 2007;17:623-628.
106. 106. Sonoda K, Miyamoto S, Hirakawa T, et al. Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol Oncol 2006;103:924-931. (Pubitemid 44821316)
107. Sonoda K, Miyamoto S, Hirakawa T, et al. Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol Oncol 2005;99:189-198.
108. Kawano Y, Kaku T, Sonoda K, et al. Expression of RCAS1 in female genital organs. Int J Gynecol Pathol 2005;24:330334.
109. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-929. (Pubitemid 20340625)
110. Bailey J, Tailor A, Naik R, et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary centre: does it identify the correct cases? Int J Gynecol Cancer 2006;16: 30-34.
111. Andersen ES, Knudsen A, Rix P, et al. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 2003;90:109-112. (Pubitemid 37338084)
112. Hricak H, Yu KK. Radiology in invasive cervical cancer. AJR Am J Roentgenol 1996;167:1101-1108.
113. Folien M, Levenback CF, Iyer RB, et al. Imaging in cervical cancer. Cancer 2003;98:2028-2038.
114. Magee BJ, Logue JP, Swindell R, et al. Tumor size as a prognostic factor in carcinoma of the cervix: assessment by transrectal ultrasound. Br J Radiol 1991;64:812-815.
115. Alcazar JL, Castillo G, Martinez-Monge R, et al. Transvaginal color doppler sonography for predicting response to concurrent chemoradiotherapy for locally advanced cervical carcinoma. J Clin Ultrasound 2004;32:267-272. (Pubitemid 38857139)
116. Chen CA, Cheng WF, Lee CN, et al. Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstet Gynecol Scand 2004;83:591-597.
117. Greco P, Cormio G, Vimercati A, et al. Transvaginal color doppler sonography in predicting the response to chemotherapy in advanced cervical cancer. Ultrasound Obstet Gynecol 1997;9:49-52. (Pubitemid 27160627)
118. Andreopoulou E, Andreopoulos D, Adamidis K, et al. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res 2002;22:19031908. (Pubitemid 34839218)
119. Kumar P, Rehani MM, Kumar L, et al. Potential of CT-scan based tumor volume as a response indicator in chemotherapy of advanced epithelial ovarian cancer. Med Sei Monit 2002;8:667-674.
120. Qayyum A, Coakley FV, Westphalen AC, et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005;96:301-306. (Pubitemid 40127125)
121. Taieb S, Leblanc E, Bonodeau F, et al. Predictive value of abdominopelvic scan for optimal surgery of ovarian carcinoma. J Gynecol Obstet Biol Reprod 2000;29:555-563. (Pubitemid 30840866)
122. Subak LL, Hricak H, Powell CB, et al. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 1995;86:43-50.
123. Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy- D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12: 97-106. (Pubitemid 43166182)
124. Amthauer H, Denecke T, Rau B, et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med MoI Imaging 2004;31:811-819. (Pubitemid 38758350)
125. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using ([18]F)-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-1688.
126. Flamen P, van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-368. (Pubitemid 34704995)
127. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-4610. (Pubitemid 46594034)
128. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-7453. (Pubitemid 46291806)
129. Grigsby PW, Dehdashti F, Siegel BA. FDG-PET evaluation of carcinoma of the cervix. Clin Positron Imaging 1999;2:105109.
130. Lin LL, Yang Z, Mutic S, et al. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int J Radiat Oncol Biol Phys 2006; 65:177-181.
131. Rose PG, Adler LP, Rodriguez M, et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999;17:41-45. (Pubitemid 29022376)
132. Grigsby PW, Mutch DG, Rader J, et al. Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys 2005;61:444-449. (Pubitemid 40164439)
133. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiât Oncol Biol Phys 2002;53:353-359.
134. Risum S, Hogdall C, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol 2007;105:145-149. (Pubitemid 46454333)
135. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007;106:29-34. (Pubitemid 46908743)
136. Chung HH, Kang WJ, Kim JW, et al. Role of (18F) FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med MoI Imaging 2007;34:480-486.
137. Hauth EA, Antoch G, Stattaus J, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005;56:263-268. (Pubitemid 41483027)
138. Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007;105:17-22. (Pubitemid 46441448)
139. Chung HH, Jo H, Kang WJ, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529-534. (Pubitemid 46240239)
140. Simcock B, Neesham D, Quinn M, et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103:271-276. (Pubitemid 44374699)
141. Chung HH, Kim SK, Kim TH, et al. Clinical impact of FDGPET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006; 103:165-170.
142. Amit A, Beck D, Lowenstein L, et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006;100:65-69. (Pubitemid 41815051)
143. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407-422.
144. Knopp MV, Giesel FL, Marcos H, et al. Dynamic contrastenhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001;12:301-308. (Pubitemid 33031399)
145. Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006;239:361-364.
146. Esserman L, Hylton N, George T, et al. Contrast-enhanced magnetic resonance imaging to assess tumor histopathol- ogy and angiogenesis in breast carcinoma. Breast J 1999;5: 13-21. (Pubitemid 29108803)
147. Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005;91:1-10. (Pubitemid 40684933)
148. George ML, Dzik-Jurasz AS, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001;88:1628-1636.
149. Fuss M, Wenz F, Essig M, et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 2001;51:478-482. (Pubitemid 32884295)
150. Hricak H, Swift PS, Campos Z, et al. Irradiation of the cervix uteri: value of unenhanced and contrast-enhanced MR imaging. Radiology 1993;189:381-388. (Pubitemid 23321414)
151. van Vierzen PB, Massuger LF, Ruys SH, et al. Fast dynamic contrast enhanced MR imaging of cervical carcinoma. Clin Radiol 1998;53:183-192.
152. Boss EA, Massuger LF, Pop LA, et al. Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma. J Magn Reson Imaging 2001;13:600-606.
153. Mayr NA, Yuh WT, Magnotta VA, et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996;36:623-633.
154. Mayr NA, Yuh WT, Zheng J, et al. Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol 1998;170:177-182. (Pubitemid 28130602)
155. Loncaster JA, Carrington BM, Sykes JR, et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiât Oncol Biol Phys 2002;54:759-767.
156. Cooper RA, Carrington BM, Loncaster JA, et al. Tumor oxygenation levels correlate with dynamic contrastenhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000;57:53-59.
157. Yamashita Y, Baba T, Baba Y, et al. Dynamic contrastenhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000;216:803-809. (Pubitemid 30660858)
158. Gong QY, Brunt JN, Romaniuk CS, et al. Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: early prediction of tumor regression rate. Br J Radiol 1999; 72:1177-1184.
159. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92: 2029-2036.
160. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sei USA 2005;102:5524-5529.
161. Pickles MD, Gibbs P, Lowry M, et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006;24:843-847. (Pubitemid 44205378)
162. Naganawa S, Sato C, Kumada H, et al. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur Radiol 2005;15:71-78. (Pubitemid 40109773)
163. Sarty GE, Kendall EJ, Loewy J, et al. Magnetic resonance diffusion imaging of ovarian masses: a first experience with 12 cases. MAGMA 2004;16:182-193. (Pubitemid 38657624)